Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016', provides in depth analysis on Transforming Growth Factor Beta 1 (TGFB1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
- The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Transforming Growth Factor Beta 1 (TGFB1) Overview 8
Therapeutics Development 9
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Stage of Development 9
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Therapy Area 10
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Indication 11
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Companies 15
Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Universities/Institutes 17
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development 25
Acceleron Pharma, Inc. 25
Digna Biotech, S.L. 26
Dong Wha Pharma Co., Ltd. 27
Eli Lilly and Company 28
Huabo Biopharm Co., Ltd. 29
Isarna Therapeutics GmbH 30
Johnson & Johnson 31
Novartis AG 32
Scholar Rock, Inc. 33
Sirnaomics, Inc. 34
Taisho Pharmaceutical Holdings Co., Ltd. 35
TissueGene, Inc. 36
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles 37
ACE-1332 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Antibody to Inhibit TGFB1 for Oncology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
decorin - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
disitertide - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
DW-1029M - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
HB-001 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
HB-002 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ISTH-1047 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ISTH-1106 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
melittin - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Monoclonal Antibody to Inhibit TGF Beta1 for Oncology - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
STP-705 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
TASP-0382088 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
tonogenchoncel-L - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
XOMA-089 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Projects 60
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products 63
Transforming Growth Factor Beta 1 (TGFB1) - Featured News & Press Releases 64
Feb 16, 2016: Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer 64
Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGF�1 Latent Complex 64
May 11, 2015: TissueGene Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee 65
Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US 65
Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA 67
Nov 17, 2014: TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee 68
Nov 14, 2012: TissueGene Completes Enrollment In US Phase II Study Of TG-C In Patients With Knee Osteoarthritis 68
Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field 68
Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705 70
May 19, 2011: TissueGene Initiates Patient Enrollment For Phase II Study Of TG-C For Osteoarthritis Of Knee 70
Mar 25, 2010: Digna Biotech Announced The Results Of Disitertide Proof Of Concept Trial In The Topical Treatment Of Skin Fibrosis 71
Mar 03, 2009: TissueGene Announces Regulatory Allowance To Initiate Phase IIa Study Of TG-C In South Korea For Osteoarthritis Of The Knee 71
Oct 19, 2007: Digna Biotech Biotechnological Company and Isdin Laboratory Begin Phase II Of A Product For Scleroderma 72
Jul 24, 2006: TissueGene Initiates Phase I Clinical Trial with TG-C 72
Apr 19, 2005: RheoGene Inc. And TissueGene Inc. Sign Collaborative Agreement For Bone Regeneration And Repair Program 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Pipeline by Acceleron Pharma, Inc., H2 2016 25
Pipeline by Digna Biotech, S.L., H2 2016 26
Pipeline by Dong Wha Pharma Co., Ltd., H2 2016 27
Pipeline by Eli Lilly and Company, H2 2016 28
Pipeline by Huabo Biopharm Co., Ltd., H2 2016 29
Pipeline by Isarna Therapeutics GmbH, H2 2016 30
Pipeline by Johnson & Johnson, H2 2016 31
Pipeline by Novartis AG, H2 2016 32
Pipeline by Scholar Rock, Inc., H2 2016 33
Pipeline by Sirnaomics, Inc., H2 2016 34
Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 35
Pipeline by TissueGene, Inc., H2 2016 36
Dormant Projects, H2 2016 60
Dormant Projects (Contd..1), H2 2016 61
Dormant Projects (Contd..2), H2 2016 62
Discontinued Products, H2 2016 63